Molecule News and Research

RSS

Pharmaceutical waste forms a whole new range of contaminants

The health implications of polluting the environment weigh increasingly on our public consciousness, and pharmaceutical wastes continue to be a main culprit. Now a Tel Aviv University researcher says that current testing for these dangerous contaminants isn't going far enough.

21 Jul 2011

Receptor GPR56 could have a critical role in cancer progression

Melanoma is devastating on many fronts: rates are rising dramatically among young people, it is deadly if not caught early, and from a biological standpoint, the disease tends to adapt to even the most modern therapies, known as VEGF inhibitors.

21 Jul 2011

Adamis' APC-300 inhibits growth of prostate cancer cells

Adamis Pharmaceuticals Corporation announced today that in addition to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the growth of prostate cancer cells.

21 Jul 2011

Novel vaccine for treating heroin addiction

Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.

21 Jul 2011

FDA panel votes against novel diabetes drug citing adverse effects

An advisory panel for the US Food and Drugs Administration voted 9-6 that the FDA should not yet approve dapagliflozin, a new type of diabetes drug that makes the body dump sugar and lose weight. Signals of possible liver damage and of breast and bladder cancer worried the experts.

20 Jul 2011

Latest advances in Alzheimer's research presented at AAIC 2011

This week, more than 5,000 scientists from around the world gathered in Paris to report the latest advances in Alzheimer's research at the Alzheimer's Association International Conference 2011.

20 Jul 2011

Scientists discover cholesterol moves far slower within and between cells

Neutrons have shown the movement of cholesterol between and within cells takes far longer than previously thought. Findings could impact the treatment of a range of diseases linked to abnormal rates of cholesterol transfer.

19 Jul 2011

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

19 Jul 2011

Scientists define structure of astrovirus that causes juvenile diarrhea

Rice University scientists have defined the structure -- down to the atomic level -- of a virus that causes juvenile diarrhea. The research may help direct efforts to develop medications that block the virus before it becomes infectious.

19 Jul 2011

Stimulant addiction from bath salts causing serious and long term problems

A new stimulant addiction is causing concern among emergency doctors. At Schuylkill Medical Center in Pottsville, Pa. people were arriving so agitated, violent and psychotic that a small army of medical workers was needed to hold them down. They had taken new stimulant drugs that people are calling “bath salts,” and sometimes even large doses of sedatives failed to quiet them.

18 Jul 2011

Disrupting protein components kills mosquitoes

Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.

18 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011

New DNA sequencer will provide deeper insight into gene regulation

The Berlin Institute for Medical Systems Biology (BIMSB) of the Max Delbr-ck Center for Molecular Medicine (MDC) in Berlin, Germany, will be the first academic research institution in Continental Europe to acquire a novel DNA sequencer enabling the sequencing of single DNA molecules in real time.

16 Jul 2011

Stored red blood cells lose ability to release key anti-adhesive molecule

Donated red blood cells lose a key feature that diminishes their lifesaving power the longer they have been stored, according to researchers at Duke University Medical Center.

16 Jul 2011

Study sheds light on the way antibodies distinguish between different 'biomarkers'

A new research paper sheds light on the way antibodies distinguish between different but closely related 'biomarkers' - proteins which reveal information about the condition of the human body.

15 Jul 2011

E-cadherin may regulate up to 25% of genes within embryonic stem cells

A protein molecule that 'glues' cells together and so has a key role in cancer is also responsible for many other important functions of cells, a new study has found.

15 Jul 2011

UW scientists determine atomic architecture of sodium channel

Scientists at the University of Washington (UW) in Seattle have determined the atomic architecture of a sodium channel. The achievement opens new possibilities for molecular medicine researchers around the world in designing better drugs for pain, epilepsy, and heart rhythm disturbances.

14 Jul 2011

Cornell grants ChromaDex worldwide rights to novel manufacturing process for nicotinamide riboside

ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

USFDA approves Dr. Reddy's ANDA for Fondaparinux Sodium Injection

Dr. Reddy's Laboratories and Alchemia Limited, Brisbane, Australia announced today that Dr. Reddy's has received final approval of Dr. Reddy's ANDA for Fondaparinux Sodium Injection, a bioequivalent generic version of Arixtra, in the US market on July 11, 2011 by the United States Food & Drug Administration.

13 Jul 2011